SOD1 and amyotrophic lateral sclerosis: Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO therapies for ALS [7]; however, it failed to show significant improvement in the primary endpoint in a phase 3 trial [8].